US equities |
SPCX $167.65 ▲+5.47% NVDA $236.11 ▲+0.92% MU $1,065.46 ▼-0.88% TSLA $378.06 ▲+2.02% MSFT $526.07 ▲+1.65% SNDK $1,710.60 ▼-0.55% INTC $117.30 ▼-1.70% META $744.21 ▲+2.22%
FinancialContent

Articles published by 180 Life Sciences Corp.

News headline image
180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Granted an Additional Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Announces Review of Strategic Alternatives
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Corp. Announces Closing of $3 Million Public Offering
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren’s Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDA
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Corp. Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Announces Presentation at the Gordon Conference
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren’s Disease Treatment and Application
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s Disease
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren’s Contracture
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
180 Life Sciences to Participate in A.G.P.’s Virtual Biotech Conference to be Held November 30 – December 1, 2022
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF
News headline image
Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease
From 180 Life Sciences Corp.
Via GlobeNewswire
Tickers ATNF